П

## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| Check this box if no longer subject to |
|--|
| Section 16. Form 4 or Form 5           |
| obligations may continue. See          |
| Instruction 1(b).                      |

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

### OMB APPROVAL OMB Number: 3235-0287

| hours per response:      | 0.5 |
|--------------------------|-----|
| Estimated average burden |     |
|                          |     |

| Powell Lyn  |  |          | 2. Issuer Name and Ticker or Trading Symbol<br>BIOCRYST PHARMACEUTICALS INC [<br>BCRX ] | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)   Director 10% Owner   X Officer (give title<br>below) Other (specify<br>below) |  |  |
|---|--|----------|---|--|--|--|
| (Last) (First) (Middle)<br>4505 EMPEROR BLVD.<br>SUITE 200<br>(Street)<br>DURHAM NC 27703<br>(City) (State) (Zip) |  | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year)<br>01/16/2019                          | Senior VP - CCO  |  |  |
|   |  |          | 4. If Amendment, Date of Original Filed (Month/Day/Year)                                | 6. Individual or Joint/Group Filing (Check Applicable<br>Line)<br>X Form filed by One Reporting Person<br>Form filed by More than One Reporting<br>Person  |  |  |

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) |  |      |   |        |               |                              | Securities<br>Beneficially         | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---------------------------------|--|--|------|---|--------|---------------|------------------------------|------------------------------------|---|---|
|                                 |  |  | Code | v | Amount | (A) or<br>(D) | Price                        | Transaction(s)<br>(Instr. 3 and 4) |   |   |
| Common Stock <sup>(1)</sup>     | 01/16/2019                                 |  | М    |   | 3,046  | A             | \$3.22                       | 3,046                              | D   |   |
| Common Stock <sup>(1)</sup>     | 01/16/2019                                 |  | S    |   | 3,046  | D             | <b>\$9.27</b> <sup>(2)</sup> | 0                                  | D   |   |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)         | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | of  |       | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---|---|--|---|------------------------------|---|-----|-------|--|--------------------|--|--|---|--|--|--|
|   |   |  |   | Code                         | v | (A) | (D)   | Date<br>Exercisable  | Expiration<br>Date | Title  | Amount<br>or<br>Number<br>of<br>Shares |   |  |  |  |
| Emp.<br>Stock<br>Option<br>(Right to<br>Buy) <sup>(1)</sup> | \$3.22  | 01/16/2019                                 |   | М                            |   |     | 3,046 | 05/23/2017   | 05/23/2026         | Common<br>Stock  | 3,046                                  | \$0   | 93,427   | D  |  |

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018.

2. The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from \$9.20 to \$9.31. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

/s/ Alane P. Barnes, by power

of attorney

\*\* Signature of Reporting Person Date

01/18/2019

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\ast$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.